


SAMPLE LAB


Positive Samples (Previous 6 Months)

● Nail ● Respiratory ● Urine ● Women's Health ● Wound




Positive Samples (January 2025)

● Urine ● Wound ● Respiratory ● Women's Health ● Nail




Urine

Positive Samples (Previous 6 Months)




MDR Pathogens (January 2025)

MDR: Defined as > 1 resistance gene family detected in specimen



Pathogen Amount Per Sample (January 2025)

● 1 Pathogen ● 2 Pathogens ● 3 Pathogens ● 4 Pathogens ● 5 or more Pathogens



Resistance Gene Breakdown vs. CPD Network (January 2025)

Network percentages shown only for resistance genes that are being tested for by selected lab

| Family Name | Lab Count | Lab % | Network % |
|------------------|-----------|--------|-----------|
| Tetracycline | 376 | 50.27% | 20.01% |
| ESBL | 164 | 21.93% | 14.64% |
| Sulfonamide | 123 | 16.44% | 17.11% |
| Folate reductase | 29 | 3.88% | 4.48% |
| ampC | 20 | 2.67% | 1.38% |
| Fluoroquinolone | 18 | 2.41% | 7.81% |
| Vancomycin | 8 | 1.07% | 2.40% |
| CRE | 6 | 0.80% | 1.70% |
| Methicillin | 4 | 0.53% | 6.23% |
| Aminoglycoside | 0 | 0.00% | 2.52% |
| femA | 0 | 0.00% | 0.14% |
| Fosfomycin | 0 | 0.00% | 0.04% |
| Macrolide | 0 | 0.00% | 21.50% |

Notable Pathogens/Resistance Genes Last 3 months

| Month | MRSA | VRE | P. Aeruginosa | CRE |
|--------------|----------|----------|---------------|-----------|
| November | 4 | 3 | 24 | 4 |
| December | 3 | 2 | 12 | 1 |
| January | 1 | 4 | 19 | 6 |
| Total | 8 | 9 | 55 | 11 |

VRE: Vancomycin-Resistant Enterococcus
 CRE: Carbapenem-Resistant Enterobacteriaceae
 MRSA: Methicillin-Resistant Staphylococcus Aureus

Average Pathogens/Resistance Genes Detected Per Sample vs. CPD Network

| Lab Pathogens | Network Pathogens | Lab Resistance Genes | Network Resistance Genes |
|---------------|-------------------|----------------------|--------------------------|
| 2.20 | 2.30 | 1.85 | 2.50 |


Pathogen Breakdown vs. CPD Network (January 2025)

Network percentages shown only for pathogens that are being tested for by selected lab

| Pathogen Name | Lab Count | Lab % | Network % |
|--|-----------|--------|-----------|
| Escherichia coli | 207 | 20.97% | 26.60% |
| Actinobaculum schaalii | 151 | 15.30% | 1.48% |
| Aerococcus urinae | 110 | 11.14% | 1.11% |
| Enterococcus faecalis | 82 | 8.31% | 15.57% |
| Ureaplasma urealyticum | 69 | 6.99% | 1.54% |
| Viridans Streptococcus Group | 65 | 6.59% | 0.64% |
| Klebsiella pneumoniae | 50 | 5.07% | 8.35% |
| Corynebacterium riegellii | 30 | 3.04% | 0.42% |
| Mycoplasma hominis | 24 | 2.43% | 0.71% |
| Proteus mirabilis | 21 | 2.13% | 7.24% |
| Candida glabrata | 20 | 2.03% | 1.41% |
| Streptococcus agalactiae (Group B) | 20 | 2.03% | 2.95% |
| Pseudomonas aeruginosa | 19 | 1.93% | 3.89% |
| Enterobacter cloacae | 17 | 1.72% | 1.51% |
| Coagulase-negative staphylococcus (CoNS) | 14 | 1.42% | 1.41% |
| Candida albicans | 13 | 1.32% | 1.27% |
| Alloscardovia Omnicolens | 12 | 1.22% | 0.20% |
| Enterobacter aerogenes | 9 | 0.91% | 1.00% |
| Klebsiella oxytoca | 8 | 0.81% | 1.01% |
| Enterococcus faecium | 6 | 0.61% | 1.57% |
| Morganella morganii | 6 | 0.61% | 2.28% |
| Candida parapsilosis | 5 | 0.51% | 0.11% |
| Staphylococcus aureus | 5 | 0.51% | 1.15% |
| Citrobacter freundii | 4 | 0.41% | 0.84% |
| Acinetobacter baumannii | 3 | 0.30% | 0.99% |
| Citrobacter koseri | 3 | 0.30% | 0.18% |
| Herpes simplex virus (HSV2) | 3 | 0.30% | 0.03% |
| Candida auris | 2 | 0.20% | 0.03% |
| Chlamydia trachomatis | 2 | 0.20% | 0.03% |


Wound

Positive Samples (Previous 6 Months)




MDR Pathogens (January 2025)

MDR: Defined as > 1 resistance gene family detected in specimen



Pathogen Amount Per Sample (January 2025)

● 1 Pathogen ● 2 Pathogens ● 3 Pathogens ● 4 Pathogens ● 5 or more Pathogens



Resistance Gene Breakdown vs. CPD Network (January 2025)

Network percentages shown only for resistance genes that are being tested for by selected lab

| Family Name | Lab Count | Lab % | Network % |
|------------------|-----------|--------|-----------|
| Macrolide | 461 | 33.55% | 24.15% |
| Tetracycline | 304 | 22.13% | 19.99% |
| Folate reductase | 128 | 9.32% | 7.33% |
| Methicillin | 128 | 9.32% | 18.25% |
| ESBL | 109 | 7.93% | 6.34% |
| Sulfonamide | 105 | 7.64% | 10.13% |
| ampC | 51 | 3.71% | 2.35% |
| CRE | 34 | 2.47% | 2.25% |
| Fluoroquinolone | 26 | 1.89% | 3.17% |
| Vancomycin | 15 | 1.09% | 1.43% |
| CFR | 11 | 0.80% | 0.38% |
| Metronidazole | 2 | 0.15% | 0.07% |
| Aminoglycoside | 0 | 0.00% | 2.90% |

Notable Pathogens/Resistance Genes Last 3 months

| Month | MRSA | VRE | P. Aeruginosa | CRE |
|--------------|------------|-----------|---------------|-----------|
| November | 95 | 13 | 93 | 32 |
| December | 82 | 9 | 61 | 19 |
| January | 83 | 9 | 82 | 28 |
| Total | 260 | 31 | 236 | 79 |

VRE: Vancomycin-Resistant Enterococcus
 CRE: Carbapenem-Resistant Enterobacteriaceae
 MRSA: Methicillin-Resistant Staphylococcus Aureus

Average Pathogens/Resistance Genes Detected Per Sample vs. CPD Network

| Lab Pathogens | Network Pathogens | Lab Resistance Genes | Network Resistance Genes |
|---------------|-------------------|----------------------|--------------------------|
| 3.10 | 2.97 | 3.91 | 2.92 |


Pathogen Breakdown vs. CPD Network (January 2025)

Network percentages shown only for pathogens that are being tested for by selected lab

| Pathogen Name | Lab Count | Lab % | Network % |
|---|-----------|--------|-----------|
| Finegoldia magna | 198 | 14.78% | 6.18% |
| Staphylococcus aureus | 132 | 9.85% | 13.43% |
| Peptoniphilus harei, Peptoniphilus ivorii | 126 | 9.40% | 3.94% |
| Coagulase-negative staphylococcus (CoNS) | 104 | 7.76% | 4.60% |
| Enterococcus faecalis | 100 | 7.46% | 11.55% |
| Pseudomonas aeruginosa | 82 | 6.12% | 8.15% |
| Corynebacterium striatum | 65 | 4.85% | 2.21% |
| Streptococcus agalactiae (Group B) | 64 | 4.78% | 4.72% |
| Proteus mirabilis | 58 | 4.33% | 4.99% |
| Escherichia coli | 46 | 3.43% | 4.78% |
| Staphylococcus lugdunensis | 35 | 2.61% | 1.10% |
| Stenotrophomonas maltophilia | 31 | 2.31% | 1.31% |
| Candida albicans | 29 | 2.16% | 1.43% |
| Enterobacter cloacae | 29 | 2.16% | 2.66% |
| Klebsiella pneumoniae | 27 | 2.01% | 2.66% |
| Morganella morganii | 27 | 2.01% | 2.09% |
| Bacteroides Fragilis | 26 | 1.94% | 2.75% |
| Serratia marcescens | 22 | 1.64% | 1.40% |
| Streptococcus anginosus | 22 | 1.64% | 0.66% |
| Acinetobacter baumannii | 19 | 1.42% | 2.48% |
| Peptostreptococcus spp | 18 | 1.34% | 2.27% |
| Providencia stuartii | 17 | 1.27% | 0.51% |
| Streptococcus pyogenes (Group A) | 16 | 1.19% | 1.28% |
| Enterobacter aerogenes | 14 | 1.04% | 0.96% |
| Citrobacter freundii | 12 | 0.90% | 0.99% |
| Enterococcus faecium | 8 | 0.60% | 0.30% |
| Clostridium perfringens | 6 | 0.45% | 0.21% |
| Clostridium novyi | 4 | 0.30% | 0.12% |
| Candida auris | 2 | 0.15% | 0.09% |


Respiratory

Positive Samples (Previous 6 Months)




MDR Pathogens (January 2025)

MDR: Defined as > 1 resistance gene family detected in specimen



Pathogen Amount Per Sample (January 2025)

1 Pathogen 2 Pathogens 3 Pathogens 4 Pathogens 5 or more Pathogens



Resistance Gene Breakdown vs. CPD Network (January 2025)

Network percentages shown only for resistance genes that are being tested for by selected lab

| Family Name | Lab Count | Lab % | Network % |
|------------------|-----------|--------|-----------|
| Macrolide | 199 | 44.72% | 39.20% |
| Tetracycline | 109 | 24.49% | 23.50% |
| ESBL | 45 | 10.11% | 10.43% |
| Sulfonamide | 35 | 7.87% | 7.59% |
| Methicillin | 24 | 5.39% | 14.23% |
| Folate reductase | 17 | 3.82% | 2.00% |
| ampC | 12 | 2.70% | 1.48% |
| Fluoroquinolone | 3 | 0.67% | 1.05% |
| CRE | 1 | 0.22% | 0.32% |
| Vancomycin | 0 | 0.00% | 0.21% |

Pathogen Breakdown vs. CPD Network (January 2025)

Network percentages shown only for pathogens that are being tested for by selected lab

| Pathogen Name | Lab Count | Lab % | Network % |
|-------------------------------------|-----------|--------|-----------|
| Influenza A | 87 | 14.10% | 9.67% |
| Moraxella catarrhalis | 83 | 13.45% | 13.89% |
| Staphylococcus aureus | 66 | 10.70% | 11.72% |
| Influenza A/H3 | 53 | 8.59% | 4.87% |
| Human herpesvirus 4 (HHV4) EBV | 38 | 6.16% | 1.69% |
| Influenza A/H1-2009 | 36 | 5.83% | 4.35% |
| Haemophilus influenzae | 30 | 4.86% | 9.63% |
| Human Coronavirus OC43 | 24 | 3.89% | 2.54% |
| Human Respiratory Syncytial Virus B | 24 | 3.89% | 1.89% |
| Streptococcus pneumoniae | 22 | 3.57% | 8.66% |
| Mycoplasma pneumoniae | 19 | 3.08% | 1.21% |
| Human Respiratory Syncytial Virus A | 17 | 2.76% | 3.54% |
| Klebsiella pneumoniae | 17 | 2.76% | 1.49% |
| Influenza B | 16 | 2.59% | 0.93% |
| Human metapneumovirus | 15 | 2.43% | 1.65% |
| Pseudomonas aeruginosa | 10 | 1.62% | 0.48% |
| Human Rhinovirus #1 | 7 | 1.13% | 1.41% |
| Human Coronavirus HKU1 | 6 | 0.97% | 0.40% |
| SARS CoV-2 / S protein gene | 6 | 0.97% | 0.24% |
| Human Coronavirus NL63 | 5 | 0.81% | 1.37% |
| Human Rhinovirus #2 | 5 | 0.81% | 0.68% |
| Parainfluenza Virus 4 | 5 | 0.81% | 0.52% |
| Parainfluenza Virus 1 | 4 | 0.65% | 0.72% |
| Adenovirus #1 | 3 | 0.49% | 1.85% |
| Chlamydia pneumoniae | 3 | 0.49% | 0.12% |
| Human Coronavirus 229E | 3 | 0.49% | 0.12% |
| Human herpesvirus 5 (HHV5) CMV | 3 | 0.49% | 0.12% |
| SARS CoV-2 / N protein gene | 2 | 0.32% | 0.08% |
| Streptococcus pyogenes (Group A) | 2 | 0.32% | 0.40% |
| Human bocavirus | 1 | 0.16% | 0.12% |

Notable Pathogens/Resistance Genes Last 3 months

| Month | Covid-19 | MRSA |
|--------------|-----------|-----------|
| November | 6 | 28 |
| December | 9 | 11 |
| January | 8 | 18 |
| Total | 23 | 57 |

Average Pathogens/Resistance Genes Detected Per Sample vs. CPD Network

| Lab Pathogens | Network Pathogens | Lab Resistance Genes | Network Resistance Genes |
|---------------|-------------------|----------------------|--------------------------|
| 2.33 | 2.05 | 3.40 | 2.91 |